Seasoned healthcare and growth-stage investor with experience in private equity, venture and portfolio company operating roles.
Matthew Ottusch is a senior investor and board director who has led deal sourcing, due diligence, growth initiatives, and exits across healthcare services and healthtech.
Focuses on value creation through commercial scale-up, strategic M&A and operational improvements; engages with LPs on fundraising and portfolio governance.
Seasoned healthcare and growth-stage investor with experience in private equity, venture and portfolio company operating roles.
Matthew Ottusch is a senior investor and board director who has led deal sourcing, due diligence, growth initiatives, and exits across healthcare services and healthtech.
Focuses on value creation through commercial scale-up, strategic M&A and operational improvements; engages with LPs on fundraising and portfolio governance.
Invests primarily in growth-stage healthcare services and healthtech, applying a value-oriented growth lens that emphasizes commercial scale-up, strategic M&A and operational transformation. Allocates capital toward companies with durable clinical economics and scalable go-to-market models, favoring board-level engagement and staged commitments tied to KPI-driven milestones. Time horizon is multi-year with active governance to de-risk execution; underwriting centers on revenue unit economics, management depth, clear exit pathways and repeatable integration playbooks.
Invests primarily in growth-stage healthcare services and healthtech, applying a value-oriented growth lens that emphasizes commercial scale-up, strategic M&A and operational transformation. Allocates capital toward companies with durable clinical economics and scalable go-to-market models, favoring board-level engagement and staged commitments tied to KPI-driven milestones. Time horizon is multi-year with active governance to de-risk execution; underwriting centers on revenue unit economics, management depth, clear exit pathways and repeatable integration playbooks.
| Trades 475 | Longs Won 327/475 68% | Profit Factor 6.25 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $156,923.21 |
| Average Win $77,911.28 | Best Trade (Jul 10) $1.22M | Sharpe Ratio -12.39 |
| Average Loss -$27,531.35 | Worst Trade (Jul 10) -$711,507.4 | Z-Score 5.43 (100%) |
| Commissions $0 | Avg. Trade Length 10m 1w 5d | Expectancy $45,057.58 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 5,025 | 4,523 | 4,020 | 3,518 | 3,015 | 2,513 | 2,010 | 1,508 | 1,005 | 503 |